qwertyuiopasdfghjklzxcvbnmqwerty

uiopasdfghjklzxcvbnmqwertyuiopasd
fghjklzxcvbnmqwertyuiopasdfghjklzx
cvbnmqwertyuiopasdfghjklzxcvbnmq
wertyuiopasdfghjklzxcvbnmqwertyui
opasdfghjklzxcvbnmqwertyuiopasdfg
hjklzxcvbnmqwertyuiopasdfghjklzxc
vbnmqwertyuiopasdfghjklzxcvbnmq
wertyuiopasdfghjklzxcvbnmqwertyui
opasdfghjklzxcvbnmqwertyuiopasdfg
NIFTY OUTLOOK
hjklzxcvbnmqwertyuiopasdfghjklzxc
REPORT
vbnmqwertyuiopasdfghjklzxcvbnmq
th
28 June 2017
wertyuiopasdfghjklzxcvbnmqwertyui
opasdfghjklzxcvbnmqwertyuiopasdfg
hjklzxcvbnmrtyuiopasdfghjklzxcvbn
mqwertyuiopasdfghjklzxcvbnmqwert
yuiopasdfghjklzxcvbnmqwertyuiopas
 28th June 2017

NIFTY

NIFTY SPOT : R1:9593 R2:9673 R3:9700

PIVOT : 9536 S1:9490 S2:9455 S3:9410

NIFTY DAILY CHART

NIFTY OUTLOOK
Nifty is likely to open in a negative note. Momentum indicators like RSI are indicating towards a signal of
reversal. Yesterday nifty was able to defend the level of 9500.Intraday traders are advised to adopt buy on dips
strategy for todays trading session. Positional traders are advised to keep their stop loss at 9450 for longs while
for contra positions it should be placed at 9600.

Strategy: buy nifty around 9475 t1 9500 t2 9525 sl 9430

Name Current Value Change % Chg Open High Low

FTSE 100 (Jun
7,434.36 -12.44 -0.17 7,446.80 7,451.68 7,411.36
27)
CAC 40 (Jun 27) 5,258.58 -37.17 -0.71 5,282.87 5,284.96 5,237.67
DAX (Jun 27) 12,671.02 -99.81 -0.79 12,728.50 12,751.20 12,644.95
Nikkei 225 (Jun
20,153.70 -71.39 -0.35 20,149.20 20,224.30 20,144.88
28)
Straits Times
3,204.83 -14.7 -0.46 3,217.50 3,221.23 3,203.75
(Jun 28)
Hang Seng (Jun
25,725.50 -114.49 -0.45 25,735.21 25,821.36 25,625.71
28)
Taiwan
Weighted (Jun 10,405.25 -106.81 -1.03 10,459.17 10,459.17 10,384.86
28)
SGX Nifty (Jun
9,501.50 -15 -0.16 9,512.00 9,514.50 9,479.00
28)

WWW.EQUITYRESEARCHLAB.COM
 28th June 2017

CORPORATE NEWS

US FDA
-Announces 2 new steps to encourage generic drug development & access
-Publishes a list of off-patent branded drugs without approved generics
-Implements policy to expedite review of generic drug applications
-Policy to review generic drug applications where competition is limited

-Sangam Advisors has been awarded letter of award by Maharashtra State Power Generation Company for
design, manufacturing and commissioning 2MV grid interactive solar plant
-AU Small Finance Bank opens for subscription today, price band Rs 355-358/share
-Country Club board approves to sell off assets to reduce debt, current debt at Rs 407 crore (market
capitalisation Rs 27 crore)
-DSP Blackrock buys 4.7 lakh shares of Arrow Greentech at a price of Rs 530
-ONGC gets green nod to explore shale gas in KG basin
-Coal India receives high re-auction realisations in June: ET
-Liberty House in talks to buy in ABG Shipyard: BS
-Cadila Healthcare aims to double US business in 3 years: BS
-Raymond to invest Rs 1,400 crore in its Maharashtra plant
-Ashok Leyland to focus on commercial vehicle business: BS
-Natural gas may be included in GST, which may benefit ONGC
-Blackstone exits Jagran Prakashan: Mint
-Godrej Consumer Products eyes acquisition in skincare segment: Mint
-Indiabulls Real Estate acquires entire minority stake of 10.08 percent in unit Indiabulls Infraestate for Rs 358
crore
-Federal Bank QIP closes on Tuesday; QIP issue price at Rs 116 per share
-Anti-Trust Body okays Red Bloom's buy of 9 percent stake in ICICI Lombard: Cogencis
-Capital First raises Rs 50 crore via issue of non-convertible debentures on a private placement basis
-LIC cuts stake in Hero Motocorp by 2.03 percent to 5.14 percent
-SpiceJet launches fares starting Rs 699 for travel between July 14 -March 24.

WWW.EQUITYRESEARCHLAB.COM
 28th June 2017

ERL RESEARCH TEAM

Member Name Designation E-mail ID

Mr. Tuhinanshu Jain Research Head Tuhinanshu.jain@equityresearchlab.co.in
Mr. Manish Bimal Sr. Research Analyst Manish.bimal@equityresearchlab.co.in

DISCLAIMER

The information and views in this report, our website & all the service we provide are believed to be
reliable, but we do not accept any responsibility (or liability) for errors of fact or opinion. Users have
the right to choose the product/s that suits them the most. Investment in Stocks has its own risks.
Sincere efforts have been made to present the right investment perspective. The information contained
herein is based on analysis and up on sources that we consider reliable. We, however, do not vouch
for the accuracy or the completeness thereof. This material is for personal information and we are not
responsible for any loss incurred based upon it & takes no responsibility whatsoever for any financial
profit s or loss which may arise from the recommendations above. The stock price projections shown
are not necessarily indicative of future price performance. The information herein, together with all
estimates and forecasts, can change without notice.

Equity Research Lab does not purport to be an invitation or an offer to buy or sell any financial
instrument. Analyst or any person related to Equity Research Lab might be holding positions in the
stocks recommended. It is understood that anyone who is browsing through the site has done so at his
free will and does not read any views expressed as a recommendation for which either the site or its
owners or anyone can be held responsible for. Any surfing and reading of the information is the
acceptance of this disclaimer.

Our Clients (Paid or Unpaid), any third party or anyone else have no rights to forward or share our
calls or SMS or Report or Any Information Provided by us to/with anyone which is received directly
or indirectly by them. If found so then Serious Legal Actions can be taken. Any surfing and reading of
the information is the acceptance of this disclaimer.

ALL RIGHTS RESERVED.

WWW.EQUITYRESEARCHLAB.COM